Biotek-snakken — Marts 2021
-
Ja det bliver spændende, interessant med IL-12, kunne være fedt med en IND på et engineered cytokine. Og lyder også til, at de roder med 4-1BB, spændende i hvilken kombination det er. Og så selvfølgelig den nye platform
-
Ja præsentationen er her: https://s23.q4cdn.com/709109388/files/doc_downloads/docs_presentation/10-11-2018-PRESENTATION.pdf
-
ZYME- Sakset denne fra twitter sep.20 kommer fra patent database search. bisp. mAbs that bind to 4-1BB and address the following targets: 1. FRa 2. HER2 3. mesothelin 4. LIV-1 Since the patents have recently been made public, first clin. trials should soon follow.
-
-
https://finance.yahoo.com/quote/ITRM?p=ITRM&.tsrc=fin-srch passer kun indtil børsen åbner igen!
-
@oge - Iterum er så massivt overspekuleret, så disse udsving er jo normalen. Til gengæld er der mulighed for at swing-trade aktien - men man skal gøre sig klart, at risiko er høj. Jeg har fyldt på igen i kurs 1,20 og 1,34 - min forventning er fortsat at vi skal meget højere op (og min. en fordobling). Men som sagt ingen nyheder
-
Der er denne du kan høre hvis du vil
https://www.incommglobalevents.com/registration/client/6960/iterum-therapeutics-4th-quarter-and-full-year-2020/ -
Artikel - the path to novel antibiotics (incl. header for Iterum, Entasis, Spero, Allecra mfl.). https://www.biospace.com/article/the-path-to-novel-antibiotics/
-
Seneste "Tril-paper" (fra Tril_Investor) - https://drive.google.com/file/d/1eaWv3eDcr-sQPvGh0dVutXTI86Z0OwIj/edit
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind